Get the Stockscreener App
9.88
0.60%
-0.06
After Hours:
9.88
Envveno Medical Corp stock is traded at $9.88, with a volume of 14,374.
It is down -0.60% in the last 24 hours and down -10.59% over the past month.
enVVeno Medical Corp is a medical device company focused on the advancement of bioprosthetic (tissue-based) solutions to improve the standard of care for the treatment of venous disease. The company first developed the VenoValve, which was a surgical replacement venous valve. It is focused on its next-generation, non-surgical venous valve product, called the enVVe System which consists of the enVVe Valve, enVVe Delivery System, enVVe Nose Cone, the enVVe Delivery System Accessories, and the enVVe Crimping System. The enVVe System is designed to treat severe deep chronic venous insufficiency through a minimally invasive, catheter-based approach. It operates in a single segment, Medical Device development, located in a single geographic location, the United States.
See More
Previous Close:
$9.94
Open:
$9.9
24h Volume:
14,374
Relative Volume:
0.92
Market Cap:
$6.48M
Revenue:
-
Net Income/Loss:
$-19.47M
P/E Ratio:
-0.3871
EPS:
-25.5243
Net Cash Flow:
$-15.57M
1W Performance:
-7.49%
1M Performance:
-10.59%
6M Performance:
-59.31%
1Y Performance:
-92.27%
1-Day Range:
$9.3606
$9.90
1-Week Range:
$9.3606
$10.90
52-Week Range:
$8.67
$196.70
Envveno Medical Corp Stock (NVNO) Company Profile
Name
Envveno Medical Corp
Sector
Industry
Phone
949-261-2900
Address
70 DOPPLER, IRVINE
Compare NVNO vs ABT, SYK, MDT, BSX, EW
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NVNO
Envveno Medical Corp
|
9.88 | 6.52M | 0 | -19.47M | -15.57M | -25.52 |
ABT
Abbott Laboratories
|
82.56 | 146.87B | 45.13B | 6.28B | 7.38B | 3.5895 |
SYK
Stryker Corp
|
282.58 | 109.33B | 25.27B | 3.34B | 4.57B | 8.6358 |
MDT
Medtronic Plc
|
74.54 | 97.77B | 35.48B | 4.64B | 5.41B | 3.582 |
BSX
Boston Scientific Corp
|
53.37 | 80.16B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
77.17 | 46.04B | 6.30B | 1.07B | 1.09B | 1.8406 |
Envveno Medical Corp Stock (NVNO) Latest News
TradingKey - TradingKey
What enVVeno (NVNO) is doing that smart investors recognize (-2.26%) 2026-05-08Stock Surge - newser.com
enVVeno Medical sees cash runway into 3Q27 - TipRanks
enVVeno Medical says cash burn rate may increase to $4M-$5M per quarter - TipRanks
enVVeno Medical reports Q1 EPS ($5.89) vs. ($7.75) last year - TipRanks
enVVeno Reports Having $25M Cash on Hand in Q1 Earnings - Orange County Business Journal
enVVeno Medical Reports First Quarter 2026 Financial Results and Provides Business Update Highlighting Strategic Advancement of the enVVe System - IndyStar
With $25M on hand, enVVeno moves toward first U.S. venous valve study - Stock Titan
enVVeno Medical Announces First Quarter 2026 Financial Results and enVVe System Advancement Update - geneonline.com
EnVVeno Medical Corporation Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
enVVeno Medical (NVNO) trims Q1 loss and secures FDA IDE for pivotal enVVe TAVVE study - Stock Titan
One enVVeno Medical Insider Raised Their Stake In The Previous Year - Yahoo Finance
enVVeno Medical Receives FDA IDE Approval for Non-Surgical Replacement Venous Valve - MedTech Intelligence
enVVeno Medical secures FDA IDE approval for venous valve study - Medical Device Network
enVVeno Medical (NVNO) Secures FDA IDE Approval for Pivotal Stud - GuruFocus
enVVeno Medical announces FDA awarded IDE approval to proceed with TAVVEB study - TipRanks
enVVeno Medical Receives First-Ever FDA IDE Approval for a U.S. Pivotal Study of a Non-Surgical Replacement Venous Valve - BioSpace
enVVeno Medical Wins FDA IDE for TAVVE Trial - TipRanks
enVVeno receives FDA approval for venous valve pivotal trial By Investing.com - Investing.com South Africa
enVVeno receives FDA approval for venous valve pivotal trial - Investing.com
FDA clears enVVeno (NASDAQ: NVNO) pivotal enVVe CVI valve study - Stock Titan
FDA allows first U.S. study of a nonsurgical vein valve for 3M patients - Stock Titan
enVVeno Medical Regains Compliance with Nasdaq Minimum Bid Price Requirement - Times Reporter
NVNO enVVeno posts narrower than expected Q3 2025 loss, shares register small gains in today’s trading.CEO Statement - Newser
enVVeno (NVNO) Stock Iron Condor (Breakdown Watch) 2026-04-20Analyst Downgrade - newser.com
MSN Money - MSN
What is enVVeno Medical Corporations market position2026 Price Swings & AI Driven Stock Movement Reports - baoquankhu1.vn
enVVeno Medical Reports Full Year 2025 Financial Results and Highlights Strategic Advancement of enVVe(R) System - The Florida Times-Union
Stop Loss: What is enVVeno Medical Corporations market positionQuarterly Market Review & Technical Entry and Exit Alerts - baoquankhu1.vn
Whats the profit margin of enVVeno Medical Corporation2026 Market Mood & Risk Managed Investment Signals - baoquankhu1.vn
NVNO PE Ratio & Valuation, Is NVNO Overvalued - Intellectia AI
enVVeno Medical Shares Crash After FDA Reaffirms VenoValve Rejection - MSN
Dow Update: Is enVVeno Medical Corporation a strong candidate for buy and holdMarket Trend Report & Consistent Profit Alerts - baoquankhu1.vn
Market Wrap: Whats the MACD signal for enVVeno Medical Corporation2026 Short Interest & Daily Profit Maximizing Tips - baoquankhu1.vn
enVVeno Medical Corp (NVNO) SEC filings - GuruFocus
enVVeno Medical Corp (NVNO) Stock Earnings Transcripts - GuruFocus
enVVeno Medical Reports FY GAAP EPS of -$33.06 Amid Reverse Stock Split - Intellectia AI
Market Pulse: Whats the MACD signal for enVVeno Medical Corporation2026 Technical Patterns & Weekly Top Gainers Alerts - baoquankhu1.vn
AI Models Reiterate High-Risk, Speculative View on enVVeno Medical (NVNO) - TipRanks
enVVeno Medical reports FY25 EPS ($33.06) vs. ($44.53) last year - TipRanks
EnVVeno Medical Reports Full Year 2025 Financial Results and Highlights Strategic Advancement of EnVVe(R) System - 富途牛牛
No replacement vein valves are approved. enVVeno is pushing one toward a 2026 trial - Stock Titan
[10-K] enVVeno Medical Corp Files Annual Report - Stock Titan
enVVeno Medical 10-K: Net loss $19.5M, no revenue, EPS not disclosed - TradingView
5HJ0 Stock Price and Chart — FWB:5HJ0 - TradingView
If You Invested $1,000 in Envveno Medical Corporation (NVNO) - Stock Titan
Envveno Medical Corp Stock (NVNO) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.34%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):